Preoperative and Prognostic Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Review Based on Artificial Intelligence

por Jiang, Yu, Wang, Kang, Wang, Yu-Ran, Xiang, Yan-Jun, Liu, Zong-Han, Feng, Jin-Kai, Cheng, Shu-Qun
Publicado 2023

Prognostic Value of Microvascular Invasion in Eight Existing Staging Systems for Hepatocellular Carcinoma: A Bi-Centeric Retrospective Cohort Study

por Xiang, Yan-Jun, Wang, Kang, Zheng, Yi-Tao, Yu, Hong-Ming, Cheng, Yu-Qiang, Wang, Wei-Jun, Shan, Yun-Feng, Cheng, Shu-Qun
Publicado 2021

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study

por Zhang, Yu-Qing, Wang, Kang, Feng, Jin-Kai, Yuan, Lu-Yun, Liang, Chao, Xiang, Yan-Jun, Wang, Xu, Mao, Fei-Fei, Cheng, Shu-Qun
Publicado 2023

Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol

por Wang, Kang, Yu, Hong-Ming, Xiang, Yan-Jun, Cheng, Yu-Qiang, Ni, Qian-Zhi, Guo, Wei-Xing, Shi, Jie, Feng, Shuang, Zhai, Jian, Cheng, Shu-Qun
Publicado 2022

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treat...

por Zhu, Hong-Fei, Feng, Jin-Kai, Xiang, Yan-Jun, Wang, Kang, Zhou, Li-Ping, Liu, Zong-Han, Cheng, Yu-Qiang, Shi, Jie, Guo, Wei-Xing, Cheng, Shu-Qun
Publicado 2023

A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection: A multicenter retrospective study

por Liu, Zong‐Han, Chai, Zong‐Tao, Feng, Jin‐Kai, Hou, Yu‐Chao, Zhang, Xiu‐Ping, Chen, Zhen‐Hua, Xiang, Yan‐Jun, Guo, Wei‐Xing, Shi, Jie, Cheng, Shu‐Qun
Publicado 2023

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

por Wang, Kang, Xiang, Yan-Jun, Yu, Hong-Ming, Cheng, Yu-Qiang, Feng, Jin-Kai, Liu, Zong-Han, Shan, Yun-Feng, Zheng, Yi-Tao, Ni, Qian-Zhi, Cheng, Shu-Qun
Publicado 2023

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

por Wang, Wei‐Jun, Liu, Zong‐Han, Wang, Kang, Yu, Hong‐Ming, Cheng, Yu‐Qiang, Xiang, Yan‐Jun, Feng, Jin‐Kai, Zhou, Li‐Ping, Zhou, Hong‐Kun, Pan, Wei‐Wei, Guo, Wei‐Xing, Shi, Jie, Cheng, Shu‐Qun
Publicado 2023

Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory

por Xiang, Yan-Jun, Wang, Kang, Zheng, Yi-Tao, Feng, Shuang, Yu, Hong-Ming, Li, Xiao-Wei, Cheng, Xi, Cheng, Yu-Qiang, Feng, Jin-Kai, Zhou, Li-Ping, Meng, Yan, Zhai, Jian, Shan, Yun-Feng, Cheng, Shu-Qun
Publicado 2022

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study

por Wang, Kang, Liu, Zong-Han, Yu, Hong-Ming, Cheng, Yu-Qiang, Xiang, Yan-Jun, Zhong, Jing-Ya, Ni, Qian-Zhi, Zhou, Li-Ping, Liang, Chao, Zhou, Hong-Kun, Pan, Wei-Wei, Guo, Wei-Xing, Shi, Jie, Cheng, Shu-Qun
Publicado 2023

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal...

por Feng, Jin-Kai, Liu, Zong-Han, Fu, Zhi-Gang, Chai, Zong-Tao, Sun, Ju-Xian, Wang, Kang, Cheng, Yu-Qiang, Zhu, Hong-Fei, Xiang, Yan-Jun, Zhou, Li-Ping, Shi, Jie, Guo, Wei-Xing, Zhai, Jian, Cheng, Shu-Qun
Publicado 2022

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A prelim...

por Wang, Kang, Xiang, Yan-Jun, Yu, Hong-Ming, Cheng, Yu-Qiang, Liu, Zong-Han, Zhong, Jing-Ya, Feng, Shuang, Ni, Qian-Zhi, Zhu, Hong-Fei, Pan, Wei-Wei, Li, Jing-Jing, Liang, Chao, Zhou, Hong-Kun, Meng, Yan, Lau, Wan Yee, Cheng, Shu-Qun
Publicado 2023